Neurotrophic Keratopathy clinical trials at University of California Health

1 in progress, 0 open to eligible people

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Sorry, not currently recruiting here
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
at UCSD

Our lead scientists for Neurotrophic Keratopathy research studies include Weldon Haw, M.D..

Last updated: August 31, 2023

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2